Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Multiple myeloma (MM) is a hematologic tumor with monoclonal proliferation of malignant plasma cells in the bone marrow. Fascin (FSCN) is an actin-binding protein that plays a crucial role in cell migration and invasion, contributing to tumor metastasis. There are three members () in family However, the prognostic role of family in MM remains unclear. In this study, we used four independent Gene Expression Omnibus (GEO) datasets to explore the relationships between expression profiles and patient survival in MM. We found that was dramatically down-regulated in MM compared to normal donors ( < 0.001) and monoclonal gammopathy of undetermined significance (MGUS) ( = 0.032). Patients with high expression of and had significantly longer OS ( = 0.023 and 0.028, respectively). Univariate and multivariate analysis showed that ( = 0.003, 0.002) and ( = 0.018, 0.013) were independent favorable prognostic factors for OS in MM. Moreover, the combination of high expression of and could effectively predict both longer EFS ( = 0.046) and OS ( = 0.015). Our study suggested that and can be used as favorable biomarkers for predicting clinical outcomes in MM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974516PMC
http://dx.doi.org/10.7150/jca.53675DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
8
high expression
8
prognostic significance
4
significance family
4
family multiple
4
myeloma multiple
4
myeloma hematologic
4
hematologic tumor
4
tumor monoclonal
4
monoclonal proliferation
4

Similar Publications

Objective: International literature suggests that patients with hematological diseases are frequently referred to palliative care (PC) at a late stage. This study aims to explore the attitudes of a hemato-oncology care team toward referring patients to the PC in a fourth-level hospital in Bogotá, Distrito Capital.

Methods: This exploratory qualitative study was conducted through in-person focus groups between May 2024 and October 2024 at Clínica Universitaria Colombia in Bogotá, Colombia.

View Article and Find Full Text PDF

Modern multiple myeloma treatment enables deep and sustained responses, necessitating assessment of minimal residual disease (MRD) in the bone marrow to refine response categorization. Recently, mass spectrometry (MS)-based methods have emerged as highly sensitive tools for measuring MRD in the peripheral blood. However, the role specific MS techniques play in response categorization has yet to be established.

View Article and Find Full Text PDF

Background: Multiple myeloma (MM) remains a formidable clinical challenge due to its high relapse rate and resistance to existing therapies. Estrogen-related receptor gamma (ERRγ), a nuclear receptor critical for cellular energy metabolism, has been implicated in various cancers. but its role in MM remains unclear.

View Article and Find Full Text PDF

Background And Aim: Cancer is currently recognized as one of the leading causes of mortality worldwide. Given the limited understanding of the association between elevated erythrocyte sedimentation rate (ESR) and solid tumors (STs), this study aimed to examine ESR values at the time of malignancy diagnosis.

Methods: This cross-sectional study utilized data extracted from the medical records of cancer patients at Shahid Baghaei-2 Hospital and Shafa Hospital in Ahvaz, Iran, from February 2020 to October 2021.

View Article and Find Full Text PDF

Purpose: The study was constructed for investigating the serum expression levels of ATIC with multiple myeloma (MM) patients and its potential clinical value as a biomarker, and analyzing its association with disease stage, treatment response, genetic characteristics and prognosis.

Patients And Methods: The serum concentrations of ATIC were assessed in 186 MM patients and 201 healthy controls via ELISA, and the diagnostic efficacy was evaluated through ROC curve analysis. Correlation analysis was conducted based on clinical parameters, including common comorbidities, clinical stages, laboratory indicators, disease status, treatment response level, and pathological characteristics.

View Article and Find Full Text PDF